INVESTIGADORES
BOLONTRADE Marcela Fabiana
artículos
Título:
Modulation of the angiogenesis response through Ha-ras control, placenta growth factor, and angiopoietin expression in mouse skin carcinogenesis.
Autor/es:
LARCHER, FERNANDO; FRANCO, MARCELA; BOLONTRADE, MARCELA F., RODRIGUEZ PUEBLO, MARCELO; CASANOVA, LLANOS; NAVARRO, MANUEL; YANCOPOULOS, GEORGE; JORCANO, JOSÉ L.; CONTI, CLAUDIO J.
Revista:
MOLECULAR CARCINOGENESIS.
Editorial:
Wiley.
Referencias:
Lugar: Hoboken, N.J. ; Año: 2003 vol. 37 p. 83 - 90
ISSN:
0899-1987
Resumen:
Tumor angiogenesis is governed by a complex balance of positive and negative angiogenic factors. Development of chemically-induced mouse skin tumors appears to be highly dependent on an early burst of neovascularization. We have previously shown that Ha-ras-driven vascular endothelial growth factor (VEGF) expression plays a pivotal role in this process. However, the status of other critical positive and negative angiogenic factors throughout skin tumorigenesis has not been studied to the same extent. In the present study, we show that another VEGF family member, placenta growth factor (PlGF), was highly upregulated at all tumor stages in a ras-dependent manner. The study of angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2), ligands of receptor tyrosine kinase 2 (Tie-2), showed that while stroma-derived Ang-2 was increased, epidermal Ang-1 expression was completely abolished at early papilloma formation. Studies using epidermal tumor cell lines suggest that the disappearance of Ang-1 also depends on ras activation, extending the plethora of events controlled by this oncogene in mouse skin carcinogenesis. Our results indicated that tumor development occurred in a strong angiogenesis-prone scenario in which PlGF and Ang-2 acted cooperatively with VEGF, whereas the negative or stabilizing effect of Ang-1 was abrogated. A time-course sequence of expression of angiogenic factors expressed throughout tumor growth, as well as the identification of key signaling molecules triggering the angiogenic response, may contribute to the development and testing of antiangiogenic therapeutic strategies with this in vivo tumor model.